Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Fission Research

Executive Summary: Mdivi-1 is a selective, cell-permeable inhibitor of mitochondrial division dynamin-related GTPase 1 (DRP1) and Dnm1, used to modulate mitochondrial fission in yeast and mammalian systems (APExBIO). At 50 μM in vitro, it inhibits Drp1 self-assembly and mitochondrial division, reducing apoptosis by blocking Bid-activated Bax/Bak-dependent cytochrome c release (Qin et al., 2019). In vivo, intraperitoneal Mdivi-1 (50 mg/kg) confers neuroprotection in ischemic retinal injury models without affecting systemic parameters (APExBIO). Mdivi-1 is insoluble in water/ethanol but soluble in DMSO at ≥17.65 mg/mL, and is widely employed in apoptosis assays, mitochondrial dynamics studies, and neuroprotection research (Mito-mScarlet article). This article extends existing analyses by providing a dense, atomic review of its mechanisms, evidence base, and experimental integration.

Biological Rationale

Mitochondrial fission and fusion are core processes in regulating mitochondrial morphology, bioenergetics, and cell fate. The large GTPase DRP1 orchestrates mitochondrial division, and its dysregulation is implicated in neurodegeneration, ischemic injury, and inflammatory diseases (Qin et al., 2019). Inhibition of mitochondrial fission by targeting DRP1 is a validated approach to attenuate mitochondrial fragmentation, reduce apoptosis, and preserve organ function. Mdivi-1, a small-molecule DRP1 inhibitor from APExBIO (SKU A4472), provides researchers with a tool to selectively modulate mitochondrial division for mechanistic studies or therapeutic exploration (APExBIO).

Mechanism of Action of Mdivi-1

Mdivi-1 binds DRP1 and Dnm1, inhibiting their GTPase activity and self-assembly. This blocks the recruitment and oligomerization of DRP1 on the outer mitochondrial membrane, preventing mitochondrial constriction and scission (Dynamin-Inhibitory-Peptide article). By inhibiting DRP1-mediated fission, Mdivi-1 reduces mitochondrial fragmentation and stabilizes mitochondrial networks, thereby limiting cytochrome c release, a key event in the intrinsic apoptosis pathway. In cell models, Mdivi-1 at 50 μM potently blocks Bid-activated Bax/Bak-dependent cytochrome c release, attenuating caspase activation and apoptosis (Qin et al., 2019). Importantly, Mdivi-1 has also been shown to modulate the RIP1-RIP3-DRP1 axis, relevant to necroptosis and inflammatory responses (Qin et al., 2019).

Evidence & Benchmarks

• Mdivi-1 (50 μM) inhibits DRP1-mediated mitochondrial fission and reduces mitochondrial fragmentation in yeast and mammalian cells (Qin et al., 2019).
• Administration of Mdivi-1 (50 mg/kg, i.p.) in C57BL/6 mice increases retinal ganglion cell survival post-ischemia and decreases GFAP expression, indicating neuroprotective effects without systemic side effects (APExBIO).
• Mdivi-1 blocks Bid-activated Bax/Bak-dependent cytochrome c release, inhibiting the intrinsic mitochondrial apoptosis pathway (Qin et al., 2019).
• Mdivi-1 disrupts the RIP1-RIP3-DRP1 pathway, reducing NLRP3 inflammasome activation and ER stress in pulmonary injury models (Qin et al., 2019).
• Solubility profile: insoluble in water/ethanol, soluble in DMSO at ≥17.65 mg/mL; optimal storage as solid at -20°C (APExBIO).

For practical workflow guidance on Mdivi-1 protocols and comparative benchmarks, see our scenario-driven extension in Mdivi-1 (SKU A4472): Practical Solutions for Mitochondria. This article expands on assay design and reproducibility strategies not detailed in the present review.

For a discussion of the translational landscape and the role of DRP1 inhibition beyond apoptosis, consult Targeting Mitochondrial Dynamics: Strategic Integration, which situates Mdivi-1 within evolving therapeutic strategies and highlights the RIP1-RIP3-DRP1 axis in pulmonary dysfunction—a mechanistic area only succinctly referenced here.

Applications, Limits & Misconceptions

Mdivi-1 is widely used in basic and translational research addressing:

• Mitochondrial dynamics assays (quantitative imaging of fission/fusion events).
• Apoptosis assays (annexin V staining, cytochrome c release quantification).
• Neuroprotection models (ischemic injury, retinal ganglion cell survival).
• Inflammatory and metabolic disease models involving mitochondrial dysfunction.

Common Pitfalls or Misconceptions

• Mdivi-1 is not effective in models where mitochondrial fission is DRP1-independent.
• It should not be used in water- or ethanol-based buffers due to its insolubility; DMSO is required for stock solution preparation (APExBIO).
• Long-term storage of Mdivi-1 in solution at room temperature leads to degradation and loss of activity.
• Effects on non-mitochondrial GTPases or unrelated pathways are minimal, but off-targets should be considered in high-throughput settings.
• Mdivi-1 does not induce apoptosis directly; its primary mechanism is inhibition of mitochondrial outer membrane permeabilization (MOMP).

For advanced protocol integration and troubleshooting, Harnessing Mdivi-1: Strategic Disruption of Mitochondrial... provides nuanced workflow guidance beyond the present scope.

Workflow Integration & Parameters

Mdivi-1 is supplied as a solid and should be dissolved in DMSO to a concentration of ≥17.65 mg/mL. For in vitro assays, the standard working concentration is 50 μM, with pre-warming to 37°C or sonication recommended to enhance solubility (APExBIO). Stock solutions are stable for several months below -20°C. For in vivo studies, the typical dose is 50 mg/kg administered intraperitoneally in mice, with evidence supporting neuroprotection and no significant effects on systemic physiology such as blood pressure or behavior. Avoid repeated freeze-thaw cycles and prepare fresh aliquots for each experiment.

For scenario-driven protocol selection and comparative analysis, refer to our detailed guide (Mito-mScarlet article), which covers bench troubleshooting and cross-assay reproducibility.

Conclusion & Outlook

Mdivi-1 (A4472) from APExBIO is a cornerstone tool for dissecting mitochondrial fission, apoptosis, and neuroprotection. Its robust selectivity for DRP1, combined with a well-characterized solubility and storage profile, makes it indispensable for high-fidelity mitochondrial dynamics research. While new DRP1 inhibitors and genetic tools continue to emerge, Mdivi-1's extensive validation in disease models positions it as the reference standard. Future studies will further clarify its translational potential and resolve outstanding questions regarding off-target effects and disease-specific mechanisms, ensuring continued impact in mitochondrial biology and therapeutic development (Qin et al., 2019).